Market Place
Sourcing Support
Pulmatrix Reports Q2 2024 Results And Provides Corporate Update
13 Aug 2024 //
PR NEWSWIRE
Pulmatrix, MannKind Cross-License And Lab Transfer Deal
30 May 2024 //
PR NEWSWIRE
Pulmatrix Publishes Clinical Results For Inhaled Migraine Treatment PUR3100
15 May 2024 //
PR NEWSWIRE
Pulmatrix Announces Stopping the PUR1900 Phase 2B Study Patient Enrollment
08 Jan 2024 //
PR NEWSWIRE
Pulmatrix Announces Third Quarter 2023 Financial Results
09 Nov 2023 //
PR NEWSWIRE
Pulmatrix Announces FDA Acceptance of IND Application for PUR3100
19 Sep 2023 //
PR NEWSWIRE
Pulmatrix Announces Publication on PUR1900, Orally Inhaled Itraconazole
23 Aug 2023 //
PR NEWSWIRE
Pulmatrix Announces Second Quarter 2023 Financial Results
10 Aug 2023 //
PR NEWSWIRE
Pulmatrix Announces Submission of IND to FDA to Initiate PII Trial of PUR3100
11 Jul 2023 //
PR NEWSWIRE
Pulmatrix Presents PUR3100 Phase 1 Data at the 65th Annual Meeting
15 Jun 2023 //
PR NEWSWIRE
Pulmatrix Announces 1Q 2023 Financial Results and Provides Corporate Update
12 May 2023 //
PR NEWSWIRE
Pulmatrix Announces Year-End and Q4 Financial 2022 Results
30 Mar 2023 //
PR NEWSWIRE
Pulmatrix to Host Leader Webinar "PUR3100 for the Treatment of Acute Migraine
25 Jan 2023 //
PR NEWSWIRE
Pulmatrix to Present Data on PUR1800 at the Annual Meeting
23 Jan 2023 //
PR NEWSWIRE
Pulmatrix Announces Positive Top Line Results from a Phase 1 Study with PUR3100
04 Jan 2023 //
PR NEWSWIRE
Pulmatrix concludes subject dosing in Phase I acute migraine trial
27 Sep 2022 //
CLINICALTRIALSARENA
Pulmatrix Begins Dosing in PI Study of PUR3100 for Acute Migraine
12 Jul 2022 //
PRNEWSWIRE
Pulmatrix Announces First Quarter 2022 Financial Results
12 May 2022 //
PRNEWSWIRE
Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in COPD
21 Mar 2022 //
PRNEWSWIRE
Pulmatrix Regains Compliance With Nasdaq Listing Requirements
17 Mar 2022 //
PRNEWSWIRE
Pulmatrix Announces Expansion of Leadership Team to Progress Clinical Pipeline
01 Mar 2022 //
PRNEWSWIRE
Pulmatrix Reports Q3 2021 Financial Results and Provides Business Update
10 Nov 2021 //
PRNEWSWIRE
Pulmatrix Announces Resolution of Contract Dispute with Cipla
09 Nov 2021 //
PRNEWSWIRE
Cipla gains on resolving funding dispute with US-based Pulmatrix
09 Nov 2021 //
ECONOMICTIMES
Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE)
16 Apr 2021 //
PRNEWSWIRE
Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor
13 Apr 2021 //
PRNESWIRE
Expert Committee on Clinical Events Assessment Following COVID-19 Immunisation
04 Mar 2021 //
INFO
Pulmatrix Announces Closing of $40 Million Registered Direct Offering
16 Feb 2021 //
PRNEWSWIRE
Pulmatrix Announces Commercial Launch of FEND, an OTC Nasal Hygiene Product
21 Oct 2020 //
PRNEWSWIRE
Pulmatrix Reports Progress on Product Pipeline
22 Sep 2020 //
PRNEWSWIRE
Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize
16 Apr 2020 //
PR NEWSWIRE
Pulmatrix Announces $8.0 Million Registered Direct Offering Priced
16 Apr 2020 //
PR NEWSWIRE
Pulmatrix Receives FTD for Pulmazole for the Treatment of Asthma-ABPA
30 Jan 2020 //
PR NEWSWIRE
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer at J&J
02 Jan 2020 //
PR NEWSWIRE
Pulmatrix Receives US Patent Covering iSPERSE™ Formulations for Pulmazole
19 Aug 2019 //
PR NEWSWIRE
Pulmatrix CEO Robert Clarke Steps Down, Ted Raad Appointed Successor
17 May 2019 //
XCONOMY
Biogen exec Paul McKenzie heads to CSL as COO; Pulmatrix CEO resigns
17 May 2019 //
ENDPTS
Cipla, Pulmatrix join hands to co-develop asthma drug
16 Apr 2019 //
MONEYCONTROL
Pulmatrix signs binding agreement with Cipla worth $22M
02 Apr 2019 //
PR NEWSWIRE
Pulmatrix`s inhaled narrow spectrum kinase inhibitors receives 5 US patents
13 Feb 2019 //
PHARMABIZ
Pulmatrix Terminates Planned Offering Pursuant to Form S-1
06 Feb 2019 //
PR NEWSWIRE
Pulmatrix, Inc. Announces Pricing of Public Offering of Common Stock
28 Jan 2019 //
BIOSPACE
Pulmatrix to Present Results from the Pulmazole (PUR1900) Phase 1/1b Study
16 Nov 2018 //
PR NEWSWIRE
Pulmatrix to present pre-clinical data on PUR1800 (RV1162) at EURSIC
17 Sep 2018 //
PR NEWSWIRE
